

# **BUY**TP: Rs 3,710 | ▲ 19%

# TATA CONSULTANCY SERVICES

IT Services

08 January 2021

# Strongest Q3 in nine years - growth and margins outperform

TCS's QoQ dollar revenue growth of 5.1% beat street estimates (~3.1%) in a seasonally weak quarter. Growth was broad-based across verticals and geographies. Adj. EBIT margin stood at 26.6%, up 40bps QoQ despite salary hikes. TCV was strong at US\$ 6.8bn. We raise our target P/E to 27.4x from 24.2x backed by strong demand growth and stable margins. On rollover, we have a revised Dec'22 TP of Rs 3,710 (Rs 3,180 earlier). Being the industry leader, TCS will be the prime beneficiary of vendor consolidation. BUY.

Ruchi Burde | Seema Nayak research@bobcaps.in

**Stellar Q3 performance:** TCS reported QoQ revenue growth of 4.1% CC/5.1% USD, beating our optimistic estimates of 2.6% CC/3% USD and setting the tone for a strong Q3 for Indian IT despite seasonality. At 2.1%, YoY growth was positive for the first time since pandemic onset. Demand is robust as indicated by TCV of US\$ 6.8bn (excluding Postbank acquisition), up 13% YoY. Geographically, India grew the highest at 18.1% QoQ CC. North America was strong at 3.3% CC, followed by Europe at 2.5%. Vertical-wise, life sciences/manufacturing posted stellar growth of 5.2%/7.1% CC. BFSI/retail-CPG increased 2%/3.1% QoQ. The strong all-round showing indicates the beginning of a multi-year demand growth cycle wherein TCS will be the prime beneficiary.

Margins surprise: Adj. EBIT margin at 26.6% expanded 40bps QoQ (est. 24.7%), entering TCS's target band of 26-28% and recovering from a trough of 23.6% in Q1. Management expects to maintain margins, aided by accelerated growth.

**Strong BFSI TCV growth:** BFSI is gaining momentum with TCV at an all-time high of US\$ 2.6bn (+44% YoY), excluding Postbank. Growth was aided by closure of the Prudential deal in December. TCS is beginning to invest more in Europe as it sees opportunity there. However, UK banking remains stressed.

Ticker/Price	TCS IN/Rs 3,121
Market cap	US\$ 159.9bn
Shares o/s	3,753mn
3M ADV	US\$132.8mn
52wk high/low	Rs 3,128/Rs 1,506
Promoter/FPI/DII	72%/17%/11%
C NCE	

Source: NSE

#### STOCK PERFORMANCE



Source: NSE

#### **KEY FINANCIALS**

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	1,464,630	1,569,490	1,662,306	2,106,950	2,489,786
EBITDA (Rs mn)	395,050	421,100	467,862	603,187	702,831
Adj. net profit (Rs mn)	315,240	323,400	337,873	444,595	518,335
Adj. EPS (Rs)	84.0	86.2	91.3	120.2	140.1
Adj. EPS growth (%)	25.3	2.6	6.0	31.6	16.6
Adj. ROAE (%)	35.5	37.0	37.7	43.6	42.1
Adj. P/E (x)	37.2	36.2	34.2	26.0	22.3
EV/EBITDA (x)	29.5	27.7	24.9	19.4	16.6

Source: Company, BOBCAPS Research



# Other highlights

- TCS is confident of achieving strong double-digit growth in FY22, backed by an uptick in cloud, products & platforms and revenue from captive acquisitions. Management is positive on BFSI momentum despite a high base. (see our report Deep Dive 3: Swift BFSI recovery ahead; raise TCS to BUY).
- Ignio (cognitive automation product) has acquired eight new logos and seven customer go-lives in Q3. TCS also launched Cognix – its AI-driven humanmachine collaboration suite in Q3FY21.
- Attrition at 7.6% during the quarter was at its lowest ever, despite net addition of 15,721 employees.
- The board has declared a third interim dividend of Rs 6/sh.
- Cash conversion stood strong at 137% of net profit.

FIG 1 - QUARTERLY PERFORMANCE

(Rs mn)	Q3FY21	Q3FY20	Y <sub>0</sub> Y (%)	Q2FY21	Q <sub>0</sub> Q (%)
Revenues (US\$ mn)	5,702	5,586	2.1	5,424	5.1
Revenue (Rs mn)	420,150	398,540	5.4	401,350	4.7
Operating Expenditure	298,080	289,830	2.8	286,220	4.1
Cost of revenues	237,490	226,820	4.7	229,580	3.4
as % of sales	56.5	56.9	-	57.2	-
SG&A expenses	60,590	63,010	(3.8)	56,640	7.0
as % of sales	14.4	15.8	-	14.1	-
EBITDA	122,070	108,710	12.3	115,130	6.0
Depreciation	10,230	8,970	14.0	9,980	2.5
EBIT	111,840	99,740	12.1	105,150	6.4
Other Income	5,080	5,950	(14.6)	7,400	(31.4)
PBT	116,920	105,690	10.6	112,550	3.9
Total Tax	29,650	24,260	22.2	25,330	17.1
Adjusted PAT	87,270	81,430	7.2	87,220	0.1
(Profit)/loss from JV's/Ass/MI	(260)	(250)	-	(290)	-
APAT after MI	87,010	81,180	7.2	86,930	0.1
Reported PAT	87,010	81,180	7.2	86,930	0.1
Reported EPS	23.2	21.6	7.3	23.2	0.2
Margins (%)			(bps)		(bps)
EBITDA	29.1	27.3	180	28.7	40
EBIT	26.6	25.0	160	26.2	40
EBT	27.8	26.5	130	28.0	(20)
PAT	20.7	20.4	30	21.7	(100)
Effective Tax rate	25.4	23.0	240	22.5	290

Source: BOBCAPS Research



## FIG 2 - OPERATING METRICS

(in US\$ mn)	Q3FY21 (% Contr. to Revenue)	Q <sub>0</sub> Q (%)	Y <sub>0</sub> Y (%)
Deal win TCV (US\$ mn)	6,800	(20.9)	13.3
Revenue by Geography			
Americas	49.1	3.4	0.0
UK	15.7	6.5	0.8
Europe	16.2	4.5	11.0
India	5.6	17.7	0.3
Asia Pac	9.7	5.1	6.5
Ibero America	1.7	5.1	2.0
MEA	2.0	10.7	(7.2)
Revenue by Domain			
BFSI	31.3	3.1	5.1
Manufacturing	9.6	7.4	(2.0)
Telecom & Media	6.6	6.7	(3.8)
Life Sciences & Healthcare	9.8	5.1	20.5
Retail & CPG	14.5	4.4	(2.6)
Technology & Services	8.6	1.6	4.5
Regional Markets & Others	19.6	9.0	(3.3)

	Q3FY21	Q2FY21	Q3FY20
Attrition (LTM) (%)	7.6	8.9	12.2

Source: BOBCAPS Research



# Valuation methodology


Following a strong Dec'20 quarter on all counts, we roll over to a new Dec'22 target price of Rs 3,710 (Rs 3,180 earlier) based on an upgraded one-year forward P/E multiple of 27.4x (24.2x earlier) which is +2sd above the last five-year mean P/E of 21x. We keep FY22/FY23 EPS estimates largely unchanged. The P/E upgrade is justified by TCS's industry-leading position which makes it the prime beneficiary of the upcoming technology upcycle, growing cloud migration demand and vendor consolidation. Reiterate BUY.

FIG 3 - REVISED ESTIMATES

(D. )		FY21E			FY22E			FY23E	
(Rs mn) -	Old	New	Change (%)	Old	New	Change (%)	Old	New	Change (%)
Revenues (US\$ mn)	22,215	22,286	0.3	27,382	27,534	0.6	31,889	31,920	0.1
YoY growth (%)	0.8	0.8	-	23.3	23.5	-	16.5	15.9	-
Revenues	1,673,534	1,662,306	(0.7)	2,135,763	2,106,950	(1.3)	2,487,379	2,489,786	0.1
EBITDA	454,419	467,862	3.0	611,431	603,187	(1.3)	702,151	702,831	0.1
EBITDA margins (%)	27.2	28.1	-	28.6	28.6	-	28.2	28.2	-
Net profits	327,360	337,873	3.2	450,338	444,595	(1.3)	517,277	518,335	0.2
EPS (Rs)	88.5	91.3	3.2	121.7	120.2	(1.3)	139.8	140.1	0.2

Source: BOBCAPS Research

FIG 4 - RELATIVE STOCK PERFORMANCE



Source: NSE

# Key risks

Key downside risks to our estimates are:

- non-conversion of TCV, and
- another wave of Covid-19.



## **FINANCIALS**

## Income Statement

Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue	1,464,630	1,569,490	1,662,306	2,106,950	2,489,786
EBITDA	395,050	421,100	467,862	603,187	702,831
Depreciation	20,550	35,300	39,533	40,859	44,978
EBIT	374,500	385,800	428,329	562,327	657,853
Net interest income/(expenses)	0	0	0	0	0
Other income/(expenses)	41,130	36,680	19,935	23,456	24,956
Exceptional items	0	0	0	0	0
EBT	415,630	422,480	448,264	585,783	682,809
Income taxes	100,010	98,010	109,231	140,588	163,874
Extraordinary items	0	0	0	0	0
Min. int./Inc. from associates	(380)	(1,070)	(1,160)	(600)	(600)
Reported net profit	315,240	323,400	337,873	444,595	518,335
Adjustments	0	0	0	0	0
Adjusted net profit	315,240	323,400	337,873	444,595	518,335

## **Balance Sheet**

Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Accounts payables	0	0	0	0	0
Other current liabilities	250,000	292,440	286,918	363,665	429,744
Provisions	0	0	0	0	0
Debt funds	440	69,060	69,060	69,060	69,060
Other liabilities	0	0	0	0	0
Equity capital	3,750	3,750	3,750	3,750	3,750
Reserves & surplus	0	0	0	0	0
Shareholders' fund	898,990	847,490	943,871	1,095,038	1,364,446
Total liabilities and equities	1,149,430	1,208,990	1,299,850	1,527,763	1,863,250
Cash and cash eq.	72,240	86,460	88,955	186,928	367,609
Accounts receivables	273,460	305,320	364,341	404,073	477,493
Inventories	0	0	0	0	0
Other current assets	243,530	239,510	273,256	346,348	409,280
Investments	349,540	273,760	273,760	273,760	273,760
Net fixed assets	113,740	198,410	192,123	193,403	198,221
CWIP	0	0	0	0	0
Intangible assets	18,790	19,930	19,930	19,930	19,930
Deferred tax assets, net	26,560	28,280	28,280	28,280	28,280
Other assets	51,570	57,320	59,205	75,042	88,677
Total assets	1,149,430	1,208,990	1,299,850	1,527,764	1,863,251

Source: Company, BOBCAPS Research



## Cash Flows

Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Net income + Depreciation	236,600	359,770	378,566	486,054	563,913
Interest expenses	(25,640)	(36,680)	(19,935)	(23,456)	(24,956)
Non-cash adjustments	0	0	0	0	0
Changes in working capital	(21,690)	8,850	(100,174)	(51,914)	(83,909)
Other operating cash flows	96,660	(2,965)	0	0	0
Cash flow from operations	285,930	328,975	258,457	410,685	455,047
Capital expenditures	(21,320)	(119,970)	(33,246)	(42,139)	(49,796)
Change in investments	73,820	(75,780)	0	0	0
Other investing cash flows	(36,050)	36,680	19,935	23,456	24,956
Cash flow from investing	16,450	(159,070)	(13,311)	(18,683)	(24,840)
Equities issued/Others	0	0	(80,000)	(80,000)	0
Debt raised/repaid	(1,940)	0	0	0	0
Interest expenses	(162,310)	0	0	0	0
Dividends paid	(114,720)	(155,685)	(162,652)	(214,028)	(249,526)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(278,970)	(155,685)	(242,652)	(294,028)	(249,526)
Changes in cash and cash eq.	23,410	14,220	2,494	97,974	180,681
Closing cash and cash eq.	72,240	86,460	88,955	186,928	367,609

## Per Share

Y/E 31 Mar (Rs)	FY19A	FY20A	FY21E	FY22E	FY23E
Reported EPS	84.0	86.2	91.3	120.2	140.1
Adjusted EPS	84.0	86.2	91.3	120.2	140.1
Dividend per share	30.0	34.5	36.5	48.1	56.0
Book value per share	239.5	225.8	255.1	296.0	368.8

## Valuations Ratios

Y/E 31 Mar (x)	FY19A	FY20A	FY21E	FY22E	FY23E
EV/Sales	8.0	7.4	7.0	5.6	4.7
EV/EBITDA	29.5	27.7	24.9	19.4	16.6
Adjusted P/E	37.2	36.2	34.2	26.0	22.3
P/BV	13.0	13.8	12.2	10.5	8.5

# **DuPont Analysis**

Y/E 31 Mar (%)	FY19A	FY20A	FY21E	FY22E	FY23E
Tax burden (Net profit/PBT)	75.8	76.5	75.4	75.9	75.9
Interest burden (PBT/EBIT)	111.0	109.5	104.7	104.2	103.8
EBIT margin (EBIT/Revenue)	25.6	24.6	25.8	26.7	26.4
Asset turnover (Revenue/Avg TA)	131.1	133.1	132.5	149.0	146.8
Leverage (Avg TA/Avg Equity)	1.3	1.4	1.4	1.4	1.4
Adjusted ROAE	35.5	37.0	37.7	43.6	42.1

Source: Company, BOBCAPS Research | Note: TA = Total Assets



# Ratio Analysis

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
YoY growth (%)					
Revenue	19.0	7.2	5.9	26.7	18.2
EBITDA	21.5	6.6	11.1	28.9	16.5
Adjusted EPS	25.3	2.6	6.0	31.6	16.6
Profitability & Return ratios (%)					
EBITDA margin	27.0	26.8	28.1	28.6	28.2
EBIT margin	25.6	24.6	25.8	26.7	26.4
Adjusted profit margin	21.5	20.6	20.3	21.1	20.8
Adjusted ROAE	35.5	37.0	37.7	43.6	42.1
ROCE	34.3	35.8	36.9	45.0	48.9
Working capital days (days)					
Receivables	65	67	74	67	65
Inventory	0	0	0	0	0
Payables	78	86	89	79	81
Ratios (x)					
Gross asset turnover	12.8	10.1	8.5	10.9	12.7
Current ratio	2.6	2.4	2.7	2.8	3.1
Net interest coverage ratio	NA	NA	NA	NA	NA
Adjusted debt/equity	(0.1)	0.0	0.0	(0.1)	(0.2)

Source: Company, BOBCAPS Research



## Disclaimer

#### Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


ADD - Expected return from >+5% to +15%

**REDUCE** - Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

#### RATINGS AND TARGET PRICE (3-YEAR HISTORY): TATA CONSULTANCY SERVICES (TCS IN)



B - Buy, A - Add, R - Reduce, S - Sell

#### Rating distribution

As of 31 December 2020, out of 88 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 43 have BUY ratings, 14 have ADD ratings, 6 are rated REDUCE and 25 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

#### **Analyst certification**

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

#### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.